Loading
A phase 2 trial of Rocbrutinib, Bendamustine, Rituximab in diffuse large b-cell lymphoma, run by Guangzhou Lupeng Pharmaceutical Company LTD., now recruiting.
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma is a phase 2 interventional study registered as NCT07189065 by Guangzhou Lupeng Pharmaceutical Company LTD., with 150 participants planned, started 2025-11-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: Rocbrutinib, Bendamustine, Rituximab, Lenalidomide. Conditions listed: Diffuse Large B-Cell Lymphoma (DLBCL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rocbrutinib, Lupeng Pharmaceuticals, Diffuse large B-cell lymphoma.
Shares Rocbrutinib, Lupeng Pharmaceuticals.
Shares Rocbrutinib, Lupeng Pharmaceuticals.
Shares Bendamustine, Lenalidomide, Rituximab.
Shares Rituximab, Diffuse large B-cell lymphoma.
Shares Bendamustine, Rituximab, Diffuse large B-cell lymphoma.
Shares Bendamustine, Rituximab.
Shares Lenalidomide, Rituximab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/